Centerstone has begun a new therapy program for individuals seeking treatment for severe depression at our Florida location.
About the Program
We are now certified to offer Spravato, a nasal spray that contains the FDA-approved medication Esketamine, and ketamine infusion therapy for people who have been treated for depression with no improvement in symptoms.
Both Spravato and ketamine infusion therapy are administered under the supervision of a medical professional, and patients are required to complete a comprehensive screening with a Centerstone physician prior to receiving treatment. Ketamine infusion therapy lasts approximately four hours for each dosage; Esketamine treatment takes approximately two hours.
Screenings and treatments are scheduled at our Bradenton, Fla., locations.
The Johnson & Johnson Patient Assistance Foundation Inc. (JJPAF) is an independent, nonprofit organization committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. For more information, visit jjpaf.org.
Once Spravato has been prescribed, Janssen CarePath can help you find the resources you may need to help get started on the medication and stay on track. For more information, visit janssencarepath.com.
Frequently Asked Questions
What are Ketamine and Esketamine?
- Ketamine is a medication traditionally used for anesthesia during surgery that was approved for use in the United States in 1970. While it does have a history as a drug of abuse, it is a safe and valuable medication when properly administered by a trained medical professional.
- Esketamine was introduced as an anesthetic in Germany in 1997 and was then marketed in other countries. It is part of ketamine but differs slightly on a molecular level.
How long have they been used to treat depression?
- For the past decade or so, researchers began studying the use of ketamine as an application for Treatment-Resistant Depression (TRD). Studies indicated that ketamine was highly successful at reducing symptoms of depression; some indicated relief of symptoms in about 80% of people prescribed. Despite their molecular differences, ketamine and Esketamine act essentially the same in their uses and effectiveness for treating TRD. Esketamine was approved by the U.S. Food and Drug Administration (FDA) in March 2019 under the drug name SpravatoTM.
When should Esketamine be considered for use?
- Esketamine is approved to treat Treatment-Resistant Depression, which is diagnosed in patients who have suffered at least one major depressive episode and have experienced at least two failed drug therapies.
How is Esketamine used in treatment?
- Spravato (Esketamine) is a fast-acting nasal spray approved for use in conjunction with an oral antidepressant in adults with Treatment-Resistant Depression.
How long does the treatment take?
- For Esketamine administration, patients will need
- 2 treatments per week for the first month (8 total)
- 1 treatment per week for the second month (4 total)
- 1 treatment every two weeks for the third month (2 total)
- The initial visit will take about 2 hours; each subsequent appointment will take about 3 hours each.
Does insurance cover treatment costs?
- Your insurance provider may cover Esketamine or Spravato. By enrolling in Janssen CarePath, you can receive guidance on submitting claims so that Spravato can be considered under your pharmacy benefits.
Do I need a referral before seeking treatment?
- If you think Esketamine may be a good fit for you, it is a good idea to talk with your health care provider, but a referral by a medical professional is not required.
When can I expect to see results?
- Patients typically begin to feel the effects within a few hours of treatment to the day after treatment. If the treatment schedule is adhered to, most patients will continue to feel the effects for up to several months.
For More Information
To learn more about the Spravato nasal spray, including answers to frequently asked questions, go online to spravato.com.
In the News
To see a report from WFLA-TV about this program, click here.
For more information about Spravato self-pay rates, ketamine infusion therapy and Centerstone’s depression care services or to make an appointment, call (941) 782-4610.